Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica PLC reports a strong first half of 2024, with an 18% increase in total revenues and a growing demand for its CDMO services, evident from a 54% growth in clients. The company is executing on its ‘One OXB’ strategy, integrating global operations and reporting a robust pipeline with contracted client orders worth approximately £94 million. Despite a decline in US revenues, the firm’s expansion in late-stage programmes and a positive revenue backlog of £120 million signal a confident outlook for future performance.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
